Growing community of inventors

Chicago, IL, United States of America

Matthew M Mack

Average Co-Inventor Count = 4.26

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 122

Matthew M MackJohn L Toner (7 patents)Matthew M MackKeith R Cromack (6 patents)Matthew M MackSandra E Burke (6 patents)Matthew M MackSyed Faiyaz Ahmed Hossainy (1 patent)Matthew M MackPaul M Consigny (1 patent)Matthew M MackShubhayu Basu (1 patent)Matthew M MackKevin Joe Ehrenreich (1 patent)Matthew M MackJeffrey Allen Spaeder (1 patent)Matthew M MackMatthew M Mack (7 patents)John L TonerJohn L Toner (24 patents)Keith R CromackKeith R Cromack (38 patents)Sandra E BurkeSandra E Burke (22 patents)Syed Faiyaz Ahmed HossainySyed Faiyaz Ahmed Hossainy (88 patents)Paul M ConsignyPaul M Consigny (68 patents)Shubhayu BasuShubhayu Basu (64 patents)Kevin Joe EhrenreichKevin Joe Ehrenreich (44 patents)Jeffrey Allen SpaederJeffrey Allen Spaeder (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Abbott Laboratories Corporation (6 from 4,177 patents)

2. Abbott Cardiovascular Systems, Inc. (1 from 1,185 patents)


7 patents:

1. 9533124 - Reperfusion injury devices

2. 8394398 - Methods of administering rapamycin analogs with anti-inflammatories using medical devices

3. 8318190 - Method of treating disorders using compositions comprising zotarolimus and paclitaxel

4. 8257726 - Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices

5. 8057816 - Compositions and methods of administering paclitaxel with other drugs using medical devices

6. 7378105 - Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens

7. 7357942 - Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/6/2025
Loading…